BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Haemonetics Corporation (HAE) Effects 2-For-1 Split of Its Common Stock


12/3/2012 9:23:38 AM

BRAINTREE, Mass., Dec. 3, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) has effected a 2-for-1 split of all shares of its common stock, in the form of a 100 percent stock dividend. Each outstanding share of the Company's pre-split common stock, including shares subject to outstanding stock options and shares available for grant under the Company's equity incentive plans, was split into two shares effective 5:00pm Eastern Time on November 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO)

The shares of common stock issued pursuant to the split will be delivered to the Company's stockholders of record as of the record date, November 9, 2012. The split affected all stockholders uniformly and did not alter any stockholder's ownership percentage. The Company's common stock will begin trading on a post-split basis on the New York Stock Exchange at the opening of trading today, December 3, 2012.

The Company expects that this split will make its shares more accessible and increase its shareholder base, thereby improving its market liquidity. Additionally this stock split reflects the Company's confidence in its strength and ability to continue to generate long term growth and financial performance.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
gerry.gould@haemonetics.com
Alt. (781) 356-9613

SOURCE Haemonetics Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES